File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1200/JCO.2020.38.15_suppl.e18519
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Peripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma
Title | Peripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma |
---|---|
Authors | |
Issue Date | 2020 |
Publisher | American Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/ |
Citation | American Society of Clinical Oncology (ASCO) 56th Annual Meeting, Virtual meeting, Chicago, USA, 29 May - 02 June 2020. In Journal of Clinical Oncology, 2020, v. 38 n. 15, Suppl., abstract no. e18519 How to Cite? |
Abstract | Background: A better understanding of peripheral cellular phenotypes in association with checkpoint inhibitors (CPI) responsiveness in recurrent/metastatic NPC could profoundly impact our knowledge of NPC immunopathology. Methods: Blood were collected from 11 patients with recurrent/metastatic NPC who received CPI (pembrolizumab) after failing second-line chemotherapy. Response to pembrolizumab was assessed by imaging and EBV DNA. Patients who achieved CR/PR were considered responsive and those with SD/PD were considered non-responsive. Four patients in the responsive group also had baseline blood before pembrolizumab. PBMC were freshly isolated and stored until analysis. For surface staining, cells were rested overnight at 37°C before resuspended in BD Brilliant stain with 2.5ng/µl Fc block for 15mins. Cells were then co-stained: 7-AAD, CD19-BV510, CD3-Alexa Fluo 700, CD4-BV510, CD279(PD-1)-BB515, CD197(CCR7)-BV421, CD45RO-APC, CD45RA-Pe-Cy5, CD8-APC-H7, CD27-PE, CD95-PE-Cy7, incubated on ice for 30mins. Samples were washed and acquired on NovoCyte Quanteon. Immune phenotypes were correlated with clinical response. Results: We found that: 1) %CD3 was upregulated in responsive group; 2) CD4/CD8 ratio did not directly stratify drug responsiveness; 3) frequency of PD1-expressing CD8+ T cells was significantly reduced in responsive group; 4) lower frequency of CCR7+PD1+CD8+ T cells in responsive group, suggesting that these may be highly differentiated and have the ability to move into peripheral sites in response to inflammatory chemokines; 5) frequency of naïve and TEMRA CD8+ T cells, but not Tscm was upregulated in responsive group; 6) finally, an interesting finding of sustained CD19+ subsets was observed in non-responsive group. Conclusions: Our results suggest that peripheral blood analysis may provide valuable insights into NPC patients’ responses to PD-1-targeted therapies. |
Description | Track:Head and Neck Cancer |
Persistent Identifier | http://hdl.handle.net/10722/290725 |
ISSN | 2023 Impact Factor: 42.1 2023 SCImago Journal Rankings: 10.639 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwong, DLW | - |
dc.contributor.author | Kam, NW | - |
dc.contributor.author | Luk, HY | - |
dc.contributor.author | Hung, TYD | - |
dc.contributor.author | Yim, MK | - |
dc.contributor.author | Lee, VHF | - |
dc.date.accessioned | 2020-11-02T05:46:14Z | - |
dc.date.available | 2020-11-02T05:46:14Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | American Society of Clinical Oncology (ASCO) 56th Annual Meeting, Virtual meeting, Chicago, USA, 29 May - 02 June 2020. In Journal of Clinical Oncology, 2020, v. 38 n. 15, Suppl., abstract no. e18519 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | http://hdl.handle.net/10722/290725 | - |
dc.description | Track:Head and Neck Cancer | - |
dc.description.abstract | Background: A better understanding of peripheral cellular phenotypes in association with checkpoint inhibitors (CPI) responsiveness in recurrent/metastatic NPC could profoundly impact our knowledge of NPC immunopathology. Methods: Blood were collected from 11 patients with recurrent/metastatic NPC who received CPI (pembrolizumab) after failing second-line chemotherapy. Response to pembrolizumab was assessed by imaging and EBV DNA. Patients who achieved CR/PR were considered responsive and those with SD/PD were considered non-responsive. Four patients in the responsive group also had baseline blood before pembrolizumab. PBMC were freshly isolated and stored until analysis. For surface staining, cells were rested overnight at 37°C before resuspended in BD Brilliant stain with 2.5ng/µl Fc block for 15mins. Cells were then co-stained: 7-AAD, CD19-BV510, CD3-Alexa Fluo 700, CD4-BV510, CD279(PD-1)-BB515, CD197(CCR7)-BV421, CD45RO-APC, CD45RA-Pe-Cy5, CD8-APC-H7, CD27-PE, CD95-PE-Cy7, incubated on ice for 30mins. Samples were washed and acquired on NovoCyte Quanteon. Immune phenotypes were correlated with clinical response. Results: We found that: 1) %CD3 was upregulated in responsive group; 2) CD4/CD8 ratio did not directly stratify drug responsiveness; 3) frequency of PD1-expressing CD8+ T cells was significantly reduced in responsive group; 4) lower frequency of CCR7+PD1+CD8+ T cells in responsive group, suggesting that these may be highly differentiated and have the ability to move into peripheral sites in response to inflammatory chemokines; 5) frequency of naïve and TEMRA CD8+ T cells, but not Tscm was upregulated in responsive group; 6) finally, an interesting finding of sustained CD19+ subsets was observed in non-responsive group. Conclusions: Our results suggest that peripheral blood analysis may provide valuable insights into NPC patients’ responses to PD-1-targeted therapies. | - |
dc.language | eng | - |
dc.publisher | American Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/ | - |
dc.relation.ispartof | Journal of Clinical Oncology | - |
dc.relation.ispartof | 56th Annual Meeting of the American Society Of Clinical Oncology (ASCO 2020) | - |
dc.title | Peripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Kwong, DLW: dlwkwong@hku.hk | - |
dc.identifier.email | Kam, NW: nwkam@hku.hk | - |
dc.identifier.email | Hung, TYD: desmondh@hku.hk | - |
dc.identifier.email | Yim, MK: paulyim@HKUCC-COM.hku.hk | - |
dc.identifier.email | Lee, VHF: vhflee@hku.hk | - |
dc.identifier.authority | Kwong, DLW=rp00414 | - |
dc.identifier.authority | Lee, VHF=rp00264 | - |
dc.description.nature | abstract | - |
dc.identifier.doi | 10.1200/JCO.2020.38.15_suppl.e18519 | - |
dc.identifier.hkuros | 318596 | - |
dc.identifier.volume | 38 | - |
dc.identifier.issue | 15, Suppl. | - |
dc.identifier.spage | abstract no. e18519 | - |
dc.identifier.epage | abstract no. e18519 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0732-183X | - |